CardioVascular Resource Group is an inspired team of senior consultants committed exclusively to the study of cardiovascular drug markets and producing the most accurate, forward-looking, and detailed market planning resources available anywhere and supporting clients with valuable expert insight.

CardioVascular Resource Group (CVrg) is a privately held consulting firm committed to evaluating the scientific, clinical and commercial potential of cardiovascular biopharmaceuticals and producing the most accurate, insightful, and robust market planning resources possible, with the express purpose of helping our clients succeed in creating winning strategies and making the right business decisions for their new products, brands, franchises, partnerships, and alliances.

CVrg’s report series in Cardiovascular Diseases delivers in-depth insight into key cardiovascular drug markets including both acute and chronic indications, producing comprehensive cornerstone resources combining up-to-date analytics with unmatched scope, depth, and accuracy.

In a field characterized by niches of unmet need and rapidly changing market dynamics, this report series aids market planners in developing strategic plans through highly granular analytics combined with expert primary research and rigorous secondary analysis. more

Cardiovascular Reports
Acute Coronary Syndromes, 2011-2020
Afib & SPAF 2011-2020
Chronic CAD, 2011-2020
Heart Failure, 2011-2020
Peripheral Arterial Disease, 2011-2020
Pulmonary Hypertension, 2011-2020
Stroke, 2011-2020
Venous Thrombosis, 2011-2020

The cardiovascular field is characterized by shared disease risk factors such as obesity, diabetes and hypertension and confluent treatment populations with complex relationships that challenge market planners. These complexities also set up a unique market landscape and provide exciting opportunities for the development of products aimed at treating underlying pathogenesis with the potential to affect large patient populations.

CVrg’s Risk Factors- Metabolic report series captures these dynamics and the underlying market-driving forces through expert primary research and rigorous secondary analysis, delivering practical and strategic assessments of opportunities and threats in the unique environment of risk factor treatment.
more

Risk Factors - Metabolic Reports
Chronic Kidney Disease, 2011-2020
Dyslipidemia / Atherosclerosis, 2011-2020
Hypertension, 2011-2020
Obesity, 2011-2020
Smoking Cessation, 2011-2020
Type 1 Diabetes, 2011-2020
Type 2 Diabetes, 2011-2020